+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Fibroblast Growth Factors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 235 Pages
  • November 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5908966
Description Jump to:
The global fibroblast growth factors (FGFs) market, which was valued at $280 million in 2024, is expected to experience robust growth over the next decade, with a projected CAGR of 8.64%. By the end of 2031, the market is anticipated to reach a valuation of $500 million. FGFs play a pivotal role in cellular proliferation, differentiation, wound healing, and tissue maintenance, making them crucial in various medical applications.

The Rising Significance of FGFs in the Medical Field:

FGFs have gained increasing importance in medical treatments, particularly in regenerating and healing tissues such as skin, muscles, tendons, bones, teeth, and nerves. The combination of FGFs with stem cells and specialized materials holds the potential to revolutionize the recovery process from injuries and diseases.

Factors Boosting the Importance of Fibroblast Growth Factors:

  • In-Depth Understanding of Wound Healing Mechanisms: Advances in molecular science have led to a comprehensive understanding of wound healing mechanisms. This knowledge is expected to pave the way for scar-free wound healing and tissue transplantation from stem cell precursors, enhancing patient care.

Challenges Hindering Sales Growth of Fibroblast Growth Factors:

  • High Development and Production Costs: The complex process of developing and producing FGFs involves significant financial investments. From extensive research to preclinical testing and clinical trials, the costs associated with FGF development pose challenges to their widespread adoption.

Country-Specific Insights:

United States: The United States is experiencing a surge in various carcinomas, driving the demand for FGFs, especially in cancer treatment. The prevalence of breast and stomach cancers has significantly contributed to this demand.
  • According to the American Society of Clinical Oncology (ASCO), approximately 297,790 women in the U.S. are expected to be diagnosed with invasive breast cancer in 2023. Additionally, stomach cancer cases are projected to reach around 26,500, with 15,930 in men and 10,570 in women in 2022.
The need for fibroblast growth factors and cytokines in the treatment of various carcinomas, coupled with government initiatives to promote research, is propelling the demand for FGFs in the United States.

Germany: Germany is at the forefront of biotechnology and regenerative medicine, focusing on the transformative potential of FGFs. Collaborations between academia, biotech companies, and government bodies are driving demand for FGFs, particularly in the treatment of chronic wounds, musculoskeletal disorders, and neurological conditions.

China: FGFs are emerging as promising targets for cancer treatment in China. Researchers are exploring FGFs' potential to disrupt tumor growth and angiogenesis, offering new avenues for cancer therapies. The country's robust biopharmaceutical industry and collaborative research initiatives are accelerating the development of FGF-targeted therapies.

Competition Landscape:

The global fibroblast growth factors market is characterized by a consolidated competitive landscape, with a few key players offering products and services on a global scale. Companies in this market are focusing on research and development, product launches, and strategic mergers to meet customer expectations and strengthen their market position.

Key Companies in the Market:

  • Thermo Fisher Scientific
  • Sigma-Aldrich (now part of Merck KGaA)
  • PeproTech
  • R&D Systems (a Bio-Techne brand)
  • Abcam
  • Cell Signaling Technology
  • Novus Biologicals

Key Segments of Fibroblast Growth Factors Industry Research:

Product:

  • FGF1
  • FGF2
  • FGF3
  • FGF4
  • FGF7
  • FGF10
  • FGF11
  • FGF12
  • FGF13
  • FGF14
  • FGF15
  • FGF18
  • FGF19
  • FGF20
  • FGF23
  • Others

Application:

  • Oncology
  • Hematology
  • Wound Healing
  • Dermatology
  • Cardiovascular Disease & Diabetes
  • Cell Culture
  • Others

End User:

  • Pharmaceutical & Biotechnology Companies
  • Research Centers & Academic Institutes
  • CMOs & CDMOs

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Fibroblast Growth Factors Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Fibroblast Growth Factors Market Outlook, 2018 - 2031
3.1. Global Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. FGF1
3.1.1.2. FGF2
3.1.1.3. FGF3
3.1.1.4. FGF4
3.1.1.5. FGF7
3.1.1.6. FGF10
3.1.1.7. FGF11
3.1.1.8. FGF12
3.1.1.9. FGF13
3.1.1.10. FGF14
3.1.1.11. FGF15
3.1.1.12. FGF18
3.1.1.13. FGF19
3.1.1.14. FGF20
3.1.1.15. FGF23
3.1.1.16. Others
3.2. Global Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Oncology
3.2.1.2. Hematology
3.2.1.3. Wound Healing
3.2.1.4. Dermatology
3.2.1.5. Cardiovascular Disease & Diabetes
3.2.1.6. Cell Culture
3.2.1.7. Others
3.3. Global Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Pharmaceutical & Biotechnology Companies
3.3.1.2. Research Centers & Academic Institutes
3.3.1.3. CMOs & CDMOs
3.4. Global Fibroblast Growth Factors Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Fibroblast Growth Factors Market Outlook, 2018 - 2031
4.1. North America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. FGF1
4.1.1.2. FGF2
4.1.1.3. FGF3
4.1.1.4. FGF4
4.1.1.5. FGF7
4.1.1.6. FGF10
4.1.1.7. FGF11
4.1.1.8. FGF12
4.1.1.9. FGF13
4.1.1.10. FGF14
4.1.1.11. FGF15
4.1.1.12. FGF18
4.1.1.13. FGF19
4.1.1.14. FGF20
4.1.1.15. FGF23
4.1.1.16. Others
4.2. North America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Oncology
4.2.1.2. Hematology
4.2.1.3. Wound Healing
4.2.1.4. Dermatology
4.2.1.5. Cardiovascular Disease & Diabetes
4.2.1.6. Cell Culture
4.2.1.7. Others
4.3. North America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Pharmaceutical & Biotechnology Companies
4.3.1.2. Research Centers & Academic Institutes
4.3.1.3. CMOs & CDMOs
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
4.4.1.2. U.S. Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
4.4.1.3. U.S. Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
4.4.1.4. Canada Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
4.4.1.5. Canada Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
4.4.1.6. Canada Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Fibroblast Growth Factors Market Outlook, 2018 - 2031
5.1. Europe Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. FGF1
5.1.1.2. FGF2
5.1.1.3. FGF3
5.1.1.4. FGF4
5.1.1.5. FGF7
5.1.1.6. FGF10
5.1.1.7. FGF11
5.1.1.8. FGF12
5.1.1.9. FGF13
5.1.1.10. FGF14
5.1.1.11. FGF15
5.1.1.12. FGF18
5.1.1.13. FGF19
5.1.1.14. FGF20
5.1.1.15. FGF23
5.1.1.16. Others
5.2. Europe Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Oncology
5.2.1.2. Hematology
5.2.1.3. Wound Healing
5.2.1.4. Dermatology
5.2.1.5. Cardiovascular Disease & Diabetes
5.2.1.6. Cell Culture
5.2.1.7. Others
5.3. Europe Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Pharmaceutical & Biotechnology Companies
5.3.1.2. Research Centers & Academic Institutes
5.3.1.3. CMOs & CDMOs
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.2. Germany Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.3. Germany Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.4. U.K. Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.5. U.K. Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.6. U.K. Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.7. France Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.8. France Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.9. France Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.10. Italy Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.11. Italy Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.12. Italy Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.13. Turkey Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.14. Turkey Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.15. Turkey Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.16. Russia Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.17. Russia Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.18. Russia Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
5.4.1.19. Rest of Europe Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
5.4.1.20. Rest of Europe Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
5.4.1.21. Rest of Europe Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Fibroblast Growth Factors Market Outlook, 2018 - 2031
6.1. Asia Pacific Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. FGF1
6.1.1.2. FGF2
6.1.1.3. FGF3
6.1.1.4. FGF4
6.1.1.5. FGF7
6.1.1.6. FGF10
6.1.1.7. FGF11
6.1.1.8. FGF12
6.1.1.9. FGF13
6.1.1.10. FGF14
6.1.1.11. FGF15
6.1.1.12. FGF18
6.1.1.13. FGF19
6.1.1.14. FGF20
6.1.1.15. FGF23
6.1.1.16. Others
6.2. Asia Pacific Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Oncology
6.2.1.2. Hematology
6.2.1.3. Wound Healing
6.2.1.4. Dermatology
6.2.1.5. Cardiovascular Disease & Diabetes
6.2.1.6. Cell Culture
6.2.1.7. Others
6.3. Asia Pacific Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Pharmaceutical & Biotechnology Companies
6.3.1.2. Research Centers & Academic Institutes
6.3.1.3. CMOs & CDMOs
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.2. China Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.3. China Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.4. Japan Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.5. Japan Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.6. Japan Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.7. South Korea Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.8. South Korea Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.9. South Korea Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.10. India Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.11. India Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.12. India Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.13. Southeast Asia Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.14. Southeast Asia Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.15. Southeast Asia Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Fibroblast Growth Factors Market Outlook, 2018 - 2031
7.1. Latin America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. FGF1
7.1.1.2. FGF2
7.1.1.3. FGF3
7.1.1.4. FGF4
7.1.1.5. FGF7
7.1.1.6. FGF10
7.1.1.7. FGF11
7.1.1.8. FGF12
7.1.1.9. FGF13
7.1.1.10. FGF14
7.1.1.11. FGF15
7.1.1.12. FGF18
7.1.1.13. FGF19
7.1.1.14. FGF20
7.1.1.15. FGF23
7.1.1.16. Others
7.2. Latin America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
7.2.1.1. Oncology
7.2.1.2. Hematology
7.2.1.3. Wound Healing
7.2.1.4. Dermatology
7.2.1.5. Cardiovascular Disease & Diabetes
7.2.1.6. Cell Culture
7.2.1.7. Others
7.3. Latin America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Pharmaceutical & Biotechnology Companies
7.3.1.2. Research Centers & Academic Institutes
7.3.1.3. CMOs & CDMOs
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.2. Brazil Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.3. Brazil Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.4. Mexico Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.5. Mexico Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.6. Mexico Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.7. Argentina Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.8. Argentina Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.9. Argentina Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
7.4.1.10. Rest of Latin America Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
7.4.1.11. Rest of Latin America Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
7.4.1.12. Rest of Latin America Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Fibroblast Growth Factors Market Outlook, 2018 - 2031
8.1. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Mn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. FGF1
8.1.1.2. FGF2
8.1.1.3. FGF3
8.1.1.4. FGF4
8.1.1.5. FGF7
8.1.1.6. FGF10
8.1.1.7. FGF11
8.1.1.8. FGF12
8.1.1.9. FGF13
8.1.1.10. FGF14
8.1.1.11. FGF15
8.1.1.12. FGF18
8.1.1.13. FGF19
8.1.1.14. FGF20
8.1.1.15. FGF23
8.1.1.16. Others
8.2. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Mn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Oncology
8.2.1.2. Hematology
8.2.1.3. Wound Healing
8.2.1.4. Dermatology
8.2.1.5. Cardiovascular Disease & Diabetes
8.2.1.6. Cell Culture
8.2.1.7. Others
8.3. Middle East & Africa Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Pharmaceutical & Biotechnology Companies
8.3.1.2. Research Centers & Academic Institutes
8.3.1.3. CMOs & CDMOs
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.2. GCC Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.3. GCC Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.4. South Africa Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.5. South Africa Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.6. South Africa Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.7. Egypt Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.8. Egypt Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.9. Egypt Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.10. Nigeria Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.11. Nigeria Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.12. Nigeria Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Fibroblast Growth Factors Market by Product, Value (US$ Mn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Fibroblast Growth Factors Market by Application, Value (US$ Mn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Fibroblast Growth Factors Market by End User, Value (US$ Mn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By End User vs by Application Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Thermo Fisher Scientific
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Sigma-Aldrich (now part of Merck KGaA)
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. PeproTech
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. R&D Systems (a Bio-Techne brand)
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Abcam
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. Cell Signaling Technology
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Novus Biologicals
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific
  • Sigma-Aldrich (now part of Merck KGaA)
  • PeproTech
  • R&D Systems (a Bio-Techne brand)
  • Abcam
  • Cell Signaling Technology
  • Novus Biologicals

Methodology

Loading
LOADING...

Related Topics

Related Reports

Fibroblast Growth Factor 1 (FGF-1) Inhibitor - Pipeline Insight, 2024 - Product Image

Fibroblast Growth Factor 1 (FGF-1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Fibroblast Growth Factor (FGF) Inhibitor - Pipeline Insight, 2024 - Product Image

Fibroblast Growth Factor (FGF) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Fibroblast Growth Factor Receptor Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology - Product Image

Fibroblast Growth Factor Receptor Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology

  • Report
  • 97 Pages
  • Global
From
Fibroblast Growth Factor 23 - Product Image

Fibroblast Growth Factor 23

  • Book
Fibroblast Growth Factors. Edition No. 2 - Product Image

Fibroblast Growth Factors. Edition No. 2

  • Book

About the Fibroblast Growth Factor Market

The Fibroblast Growth Factor (FGF) market is a segment of the genomics industry that focuses on the development of products and services related to FGFs. FGFs are proteins that play a role in cell growth, differentiation, and migration. They are involved in a variety of biological processes, including wound healing, tissue repair, and embryonic development. FGFs are also used in research and drug development, as they can be used to study the effects of various drugs on cell growth and differentiation. The FGF market is highly competitive, with a number of companies offering products and services related to FGFs. These companies include Abcam, Bio-Techne, Merck KGaA, R&D Systems, and Thermo Fisher Scientific. These companies offer a range of products, including FGFs, FGF receptors, and FGF-related antibodies. They also provide services such as FGF-related research and drug development. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.